Costs attributable to RA are expected to further increase as the population ages and the prevalence of obesity and physical inactivity increases.
The United States represents 5.4% of the world’s population; however, it consumes 80% of the world’s opioid supply, according to data from OptumRX. Further, every 16 minutes someone in the United States dies from an opioid related-cause and 4.5 million Americans are estimated to have a substance use disorder related to opioid prescription painkillers.
Sarah M Temkin, MD, and Don Dizon, MD, discuss the benefits of PARP inhibitors for treating ovarian cancer and why effectiveness, toxicity, safety, and cost must be balanced for an individual patient to determine the right PARP inhibitor for the right patient at the right time.
Richard G Wenzel, PharmD, pharmacologist at the Diamond Headache Inpatient Unit, discusses novel therapies for acute migraines that provide an opportunity to reassess migraine approaches for this undertreated and widespread illness.
Multiple sclerosis (MS) is chronic, inflammatory immune-mediated disease in which the immune system mistakenly attacks myelin in the central nervous system.
Recent advances in the ability to treat moderate to severe asthma with targeted therapies may change the game for these patients. However, cost considerations could significantly impact budgets as these new agents come to the market.
The treatment landscape for moderate to severe atopic dermatitis has changed significantly over recent months.
Kyle Schweser, MD, and Brett Crist, MD, discuss the numerous treatment options and recommendations that are currently available for osteoporosis in men and postmenopausal women.
Julia Jarmoszko, PharmD, MBA, pharmacy resident at Magellan Rx Management, discusses significant progress that has been made in understanding the burden of the psoriasis and how it is treated.
As approvals continue to gain momentum in 2018, Formulary Frontlines will continue to cover the latest breaking formulary updates for a wide range of disease states impacting specialty pharmacy spending.